Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Abcam Licenses Novel Technology from Columbia University for Neurobiological Research

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
New products from Abcam Biochemicals will support research into neurodegeneration and drug addiction.

Abcam Plc. and Columbia University, announced that they have entered into an exclusive license agreement for two novel pH-responsive fluorescent false neurotransmitters (FFNs). FFNs are probes which act as optical tracers, allowing imaging of neurotransmitter release from individual presynaptic terminals in the brain. Under the terms of the agreement, Abcam Biochemicals will provide the FFN compounds to its customers as part of the Abcam Biochemicals range, to support both fundamental and applied neurobiological research, including neurodegeneration and drug addiction.

The two FFNs licenced by Abcam are FFN102 and FFN202, which are first-of-a-kind small molecules that act as pH sensors. FFN102, which allows measurement of activity at dopamine synapses, enables the further study of synaptic plasticity by allowing optical imaging of dopaminergic presynaptic terminals. FFN202 may be used to screen drugs and other molecules to examine their effects on the pH of secretory vesicles.

Both FFN102 and FFN202 are sufficiently bright, photostable and suitable for two-photon and standard fluorescence microscopy and are compatible with GFP tags.

Steve Roome, general manager of Abcam Biochemicals explains “This is now our third collaboration with Columbia University, and we are delighted to be working with them again. Entering into such a license agreement will allow us to offer the ground-breaking FFN102 (Mini102) and FFN202 (Mini202) compounds to researchers, and both are now available as part of the Abcam Biochemicals range.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Abcam Acquires Firefly BioWorks
Acquisition will expand Abcam’s capabilities in multiplex analysis.
Wednesday, January 21, 2015
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!